A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3 mut+ acute myeloid leukemia in a US health plan
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3 mut+ acute myeloid leukemia in a US health plan
Authors
Keywords
-
Journal
JOURNAL OF MEDICAL ECONOMICS
Volume 24, Issue 1, Pages 19-28
Publisher
Informa UK Limited
Online
2020-12-07
DOI
10.1080/13696998.2020.1851698
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study
- (2019) David Cella et al. BLOOD
- The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3-Mutated (FLT3mut+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study
- (2019) Ellen K. Ritchie et al. BLOOD
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective
- (2019) Daniel Stellato et al. Journal of Managed Care & Specialty Pharmacy
- ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial
- (2018) Claudia M Gorcea et al. Future Oncology
- Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level
- (2018) Carly J. Paoli et al. CRITICAL CARE MEDICINE
- Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia
- (2018) Jun Xu et al. MEDICINE
- The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives
- (2018) Christopher A. Bly et al. Journal of Managed Care & Specialty Pharmacy
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3 -Mutated and Wild Type Acute Myeloid Leukemia: A Medical Chart Study
- (2018) James D. Griffin et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US
- (2018) Lei Wu et al. JOURNAL OF MEDICAL ECONOMICS
- Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
- (2017) Masamichi Mori et al. INVESTIGATIONAL NEW DRUGS
- Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret R. O'Donnell et al. Journal of the National Comprehensive Cancer Network
- Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population
- (2017) Aniket A. Kawatkar et al. SUPPORTIVE CARE IN CANCER
- Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic
- (2017) Darya B. Rose et al. JOURNAL OF MEDICAL ECONOMICS
- Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer
- (2017) Kyle Flannery et al. Journal of Managed Care & Specialty Pharmacy
- Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
- (2016) Lauren Y. Lee et al. BLOOD
- Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
- (2016) Irina A. Tikhonova et al. PHARMACOECONOMICS
- Activity-based costs of plasma transfusions in medical and surgical inpatients at a US hospital
- (2016) A. Shander et al. VOX SANGUINIS
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML
- (2015) Y Song et al. BONE MARROW TRANSPLANTATION
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
- (2015) Nestor Ramos et al. Journal of Clinical Medicine
- Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
- (2013) I.-K. Park et al. BLOOD
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
- (2013) F. Ravandi et al. BLOOD
- High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial
- (2013) Markus Schaich et al. JOURNAL OF CLINICAL ONCOLOGY
- Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
- (2013) Sean D. Sullivan et al. VALUE IN HEALTH
- Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
- (2012) Ellen K. Ritchie et al. LEUKEMIA & LYMPHOMA
- Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients
- (2012) Mikako Warren et al. MODERN PATHOLOGY
- Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States
- (2012) Jipan Xie et al. JOURNAL OF MEDICAL ECONOMICS
- Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007
- (2011) G. M. Dores et al. BLOOD
- Clinical and Economic Outcomes Attributable to Health Care–Associated Sepsis and Pneumonia
- (2010) Michael R. Eber ARCHIVES OF INTERNAL MEDICINE
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse
- (2009) F. Giles et al. BLOOD
- Anthracycline Dose Intensification in Acute Myeloid Leukemia
- (2009) Hugo F. Fernandez et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now